WallStreetZenWallStreetZen

NASDAQ: FATE
Fate Therapeutics Inc Stock Ownership - Who owns Fate Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Fate Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Kamal AdawiCFO2026-11-036,582$2.06
$13.53kSell
Bahram ValamehrCEO;Pres2026-08-0443,947$2.46
$108.11kSell
Cindy TahlCLO2026-08-0438,800$2.46
$95.41kSell
Bahram ValamehrPresident and CEO2026-05-2028,946$1.88
$54.48kSell
Cindy TahlChief Legal and Compliance Officer2026-05-2025,590$1.88
$48.08kSell
Cindy TahlChief Legal and Compliance Officer2026-05-06122,220$1.32
$161.33kBuy
Cindy TahlChief Legal and Compliance Officer2026-05-0644,444$1.05
$46.67kBuy
William H. RastetterDirector2026-05-0525,000$1.69
$42.25kBuy
Robert S. EpsteinDirector2026-05-0525,000$1.69
$42.25kBuy
Bahram ValamehrPresident and CEO2026-01-095,190$1.07
$5.56kSell

1 of 2

FATE insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when FATE insiders and whales buy or sell their stock.

FATE Shareholders

What type of owners hold Fate Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Redmile Group LLC21.51%25,768,554$47.29MInsider
Amir Nashat8.22%9,852,967$18.08MInsider
Polaris Venture Management Co V LLC8.21%9,841,933$18.06MInsider
Redco II Master Fund LP7.49%8,977,624$16.47MInsider
Ovp Venture Partners VII LP2.50%2,998,112$5.50MInsider
Arch Venture Fund VI LP2.06%2,473,188$4.54MInsider
Robert Nelsen2.06%2,473,188$4.54MInsider
Venrock Associates V LP2.06%2,473,187$4.54MInsider
William H. Rastetter0.63%760,784$1.40MInsider
Bahram Valamehr0.49%591,815$1.09MInsider

1 of 3

FATE vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
FATE0.06%57.33%Net BuyingNet Selling
KRRO0.04%99.96%Net BuyingNet Selling
GLSI0.01%89.01%Net Buying
ACIU0.02%4.42%Net Selling
RNAC0.02%99.98%Net Buying
View Top Biotech Stocks

Fate Therapeutics Stock Ownership FAQ

Who owns Fate Therapeutics?

Fate Therapeutics (NASDAQ: FATE) is owned by 0.06% institutional shareholders, 57.33% Fate Therapeutics insiders, and 42.61% retail investors. Redmile Group LLC is the largest individual Fate Therapeutics shareholder, owning 25.77M shares representing 21.51% of the company. Redmile Group LLC's Fate Therapeutics shares are currently valued at $47.29M.

If you're new to stock investing, here's how to buy Fate Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.